HRP20210133T1 - Kombinacija adenovirusa i inhibitora kontrolne točke u liječenju raka - Google Patents
Kombinacija adenovirusa i inhibitora kontrolne točke u liječenju raka Download PDFInfo
- Publication number
- HRP20210133T1 HRP20210133T1 HRP20210133TT HRP20210133T HRP20210133T1 HR P20210133 T1 HRP20210133 T1 HR P20210133T1 HR P20210133T T HRP20210133T T HR P20210133TT HR P20210133 T HRP20210133 T HR P20210133T HR P20210133 T1 HRP20210133 T1 HR P20210133T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- treatment
- human
- intended
- human cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16188301.2A EP3293201B1 (en) | 2016-09-12 | 2016-09-12 | Combining adenovirus and checkpoint inhibitors for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210133T1 true HRP20210133T1 (hr) | 2021-03-19 |
Family
ID=56926041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210133TT HRP20210133T1 (hr) | 2016-09-12 | 2021-01-26 | Kombinacija adenovirusa i inhibitora kontrolne točke u liječenju raka |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10940203B2 (enExample) |
| EP (2) | EP3783032A1 (enExample) |
| JP (2) | JP7146739B2 (enExample) |
| CN (1) | CN109715664A (enExample) |
| AU (1) | AU2017324482A1 (enExample) |
| DK (1) | DK3293201T3 (enExample) |
| ES (1) | ES2845690T3 (enExample) |
| HR (1) | HRP20210133T1 (enExample) |
| HU (1) | HUE053236T2 (enExample) |
| LT (1) | LT3293201T (enExample) |
| PL (1) | PL3293201T3 (enExample) |
| PT (1) | PT3293201T (enExample) |
| SI (1) | SI3293201T1 (enExample) |
| WO (1) | WO2018046803A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10350275B2 (en) * | 2013-09-21 | 2019-07-16 | Advantagene, Inc. | Methods of cytotoxic gene therapy to treat tumors |
| CN109789177A (zh) | 2016-05-27 | 2019-05-21 | 德那翠丝有限公司 | 腺病毒和免疫调节剂组合治疗 |
| EP3534923A4 (en) * | 2016-11-01 | 2020-05-27 | DNAtrix, Inc. | COMBINATION THERAPY FOR THE TREATMENT OF BRAIN CARCINOMAS |
| GB201804473D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | Modified oncolytic adenoviruses |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| AU2020385683A1 (en) | 2019-11-18 | 2022-06-30 | Janssen Biotech, Inc. | Vaccines based on mutant CALR and JAK2 and their uses |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN114426945B (zh) * | 2021-11-10 | 2024-08-23 | 西安交通大学医学院第一附属医院 | 胶质瘤类器官原代促活液、培养液及制备、培养方法 |
| CN121335710A (zh) * | 2023-04-07 | 2026-01-13 | 上海复诺健生物科技有限公司 | 重组溶瘤病毒与检查点抑制剂的组合用于治疗癌症 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2304281B1 (es) * | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
| HUE031689T2 (en) | 2008-12-22 | 2017-07-28 | Targovax Oy | Oncolytic adenoviral vectors and related procedures and applications |
| FI20090030A0 (fi) * | 2009-02-02 | 2009-02-02 | Akseli Eetu Hemminki | Onkolyyttiset virukset |
| WO2014036412A2 (en) | 2012-08-30 | 2014-03-06 | Amgen Inc. | A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor |
| WO2014047350A1 (en) | 2012-09-20 | 2014-03-27 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| US10350275B2 (en) | 2013-09-21 | 2019-07-16 | Advantagene, Inc. | Methods of cytotoxic gene therapy to treat tumors |
| KR20160137946A (ko) * | 2013-11-22 | 2016-12-02 | 디엔에이트릭스, 인코포레이티드 | 면역 세포 자극성 수용체 작용제(들)를 발현하는 아데노바이러스 |
-
2016
- 2016-09-12 LT LTEP16188301.2T patent/LT3293201T/lt unknown
- 2016-09-12 PL PL16188301T patent/PL3293201T3/pl unknown
- 2016-09-12 PT PT161883012T patent/PT3293201T/pt unknown
- 2016-09-12 HU HUE16188301A patent/HUE053236T2/hu unknown
- 2016-09-12 ES ES16188301T patent/ES2845690T3/es active Active
- 2016-09-12 SI SI201631076T patent/SI3293201T1/sl unknown
- 2016-09-12 EP EP20197744.4A patent/EP3783032A1/en not_active Withdrawn
- 2016-09-12 EP EP16188301.2A patent/EP3293201B1/en active Active
- 2016-09-12 DK DK16188301.2T patent/DK3293201T3/da active
-
2017
- 2017-09-11 CN CN201780055920.5A patent/CN109715664A/zh active Pending
- 2017-09-11 AU AU2017324482A patent/AU2017324482A1/en not_active Abandoned
- 2017-09-11 JP JP2019513967A patent/JP7146739B2/ja active Active
- 2017-09-11 WO PCT/FI2017/050645 patent/WO2018046803A1/en not_active Ceased
- 2017-09-11 US US16/330,274 patent/US10940203B2/en not_active Expired - Fee Related
-
2021
- 2021-01-05 US US17/141,463 patent/US11690913B2/en active Active
- 2021-01-26 HR HRP20210133TT patent/HRP20210133T1/hr unknown
-
2022
- 2022-09-21 JP JP2022150036A patent/JP2022183170A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019532047A (ja) | 2019-11-07 |
| HUE053236T2 (hu) | 2021-06-28 |
| DK3293201T3 (da) | 2020-12-07 |
| JP7146739B2 (ja) | 2022-10-04 |
| SI3293201T1 (sl) | 2021-03-31 |
| WO2018046803A1 (en) | 2018-03-15 |
| US10940203B2 (en) | 2021-03-09 |
| PT3293201T (pt) | 2020-12-07 |
| US20190201525A1 (en) | 2019-07-04 |
| ES2845690T3 (es) | 2021-07-27 |
| CN109715664A (zh) | 2019-05-03 |
| US11690913B2 (en) | 2023-07-04 |
| EP3783032A1 (en) | 2021-02-24 |
| AU2017324482A1 (en) | 2019-04-11 |
| LT3293201T (lt) | 2021-03-25 |
| PL3293201T3 (pl) | 2021-06-14 |
| JP2022183170A (ja) | 2022-12-08 |
| EP3293201A1 (en) | 2018-03-14 |
| US20210121564A1 (en) | 2021-04-29 |
| EP3293201B1 (en) | 2020-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210133T1 (hr) | Kombinacija adenovirusa i inhibitora kontrolne točke u liječenju raka | |
| Mantwill et al. | Concepts in oncolytic adenovirus therapy | |
| Seymour et al. | Oncolytic viruses: finally delivering | |
| Niemann et al. | Oncolytic viruses: adenoviruses | |
| JP4787936B2 (ja) | 癌処理への使用のためのキメラアデノウィルス | |
| Alemany et al. | Replicative adenoviruses for cancer therapy | |
| PH12016500759B1 (en) | Oncolytic adenoviruses armed with heterologous genes | |
| Ko et al. | Development of transcriptionally regulated oncolytic adenoviruses | |
| McCormick | Cancer specific viruses and the development of ONYX-015 | |
| Ries et al. | ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus | |
| Liu et al. | Effective gene–virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5 | |
| Guse et al. | Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models | |
| Sharma et al. | Adenoviral vector-based strategies for cancer therapy | |
| Cunliffe et al. | Hitting the target but missing the point: recent progress towards adenovirus-based precision virotherapies | |
| Tysome et al. | Update on oncolytic viral therapy–targeting angiogenesis | |
| WO2017062511A8 (en) | Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound repair and tissue regeneration | |
| SA521422495B1 (ar) | مستضدات البروستاتا المستحدثة واستخداماتها | |
| Zhou et al. | Telomerase-specific oncolytic adenovirus expressing TRAIL suppresses peritoneal dissemination of gastric cancer | |
| Luo et al. | Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene | |
| Farrera-Sal et al. | Effect of transgene location, transcriptional control elements and transgene features in armed oncolytic adenoviruses | |
| Sato-Dahlman et al. | The Development of Oncolytic Adenovirus Therapy in the Past and Future-For the Case of Pancreatic Cancer | |
| Yokoda et al. | Oncolytic virotherapy in upper gastrointestinal tract cancers | |
| Chu et al. | Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model | |
| Fillat et al. | Combining oncolytic virotherapy and cytotoxic therapies to fight cancer | |
| Guo et al. | Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models |